severe (egfr<30 ml/min) and moderate (egfr 30-60 ml/min) chronic kidney disease or requiring dialysis severe hepatic insufficiency defined as one or more of the following: cirrhosis diagnosis, serum alt > 3x uln or alkaline phosphatase >3x uln or bilirubin >2x uln in the absence of gilbert's or hemolysis, uncontrolled acute or chronic liver disease (e.g. acute hepatitis a, unstable autoimmune hepatitis) pregnancy or breast feeding. history of a seizure disorder. patient is taking fluvoxamine, capmatinib, ciprofloxacin (systemic), deferasirox, givosiran, methoxsalen (systemic), mexiletine, rucaparib, stiripentol, thiabendazole, vemurafenib, methoxsalen, sodium oxybate or echinacea. allergy to the study medication currently taking melatonin currently taking high dose (>500 mg/day) vitamin c. meets criteria for severe or critical covid-19

severe (egfr<30 ml/min) and moderate (egfr 30-60 ml/min) chronic kidney disease or requiring dialysis severe hepatic insufficiency defined as one or more of the following: cirrhosis diagnosis, serum alt > 3x uln or alkaline phosphatase >3x uln or bilirubin >2x uln in the absence of gilbert's or hemolysis, uncontrolled acute or chronic liver disease (e.g. acute hepatitis a, unstable autoimmune hepatitis) pregnancy or breast feeding. history of a seizure disorder. patient is taking fluvoxamine, capmatinib, ciprofloxacin (systemic), deferasirox, givosiran, methoxsalen (systemic), mexiletine, rucaparib, stiripentol, thiabendazole, vemurafenib, methoxsalen, sodium oxybate or echinacea. allergy to the study medication currently taking melatonin currently taking high dose (>500 mg/day) vitamin c. meets criteria for severe or critical covid-19

1. severe (egfr<30 ml/min) and moderate (egfr 30-60 ml/min) chronic kidney disease or requiring dialysis 2. severe hepatic insufficiency defined as one or more of the following: cirrhosis diagnosis, serum alt > 3x uln or alkaline phosphatase >3x uln or bilirubin >2x uln in the absence of gilbert's or hemolysis, uncontrolled acute or chronic liver disease (e.g. acute hepatitis a, unstable autoimmune hepatitis) 3. pregnancy or breast feeding. 4. history of a seizure disorder. 5. patient is taking fluvoxamine, capmatinib, ciprofloxacin (systemic), deferasirox, givosiran, methoxsalen (systemic), mexiletine, rucaparib, stiripentol, thiabendazole, vemurafenib, methoxsalen, sodium oxybate or echinacea. 6. allergy to the study medication 7. currently taking melatonin 8. currently taking high dose (>500 mg/day) vitamin c. 9. meets criteria for severe or critical covid-19

1. severe (egfr<30 ml/min) and moderate (egfr 30-60 ml/min) chronic kidney disease or requiring dialysis 2. severe hepatic insufficiency defined as one or more of the following: cirrhosis diagnosis, serum alt > 3x uln or alkaline phosphatase >3x uln or bilirubin >2x uln in the absence of gilbert's or hemolysis, uncontrolled acute or chronic liver disease (e.g. acute hepatitis a, unstable autoimmune hepatitis) 3. pregnancy or breast feeding. 4. history of a seizure disorder. 5. patient is taking fluvoxamine, capmatinib, ciprofloxacin (systemic), deferasirox, givosiran, methoxsalen (systemic), mexiletine, rucaparib, stiripentol, thiabendazole, vemurafenib, methoxsalen, sodium oxybate or echinacea. 6. allergy to the study medication 7. currently taking melatonin 8. currently taking high dose (>500 mg/day) vitamin c. 9. meets criteria for severe or critical covid-19